Stock page
Nymox Pharmaceutical Corp (NYMXF)
Nymox Pharmaceutical Corp is a biopharmaceutical company focused on developing its drug candidate, NX-1207, for the treatment of BPH and low-grade localized prostate cancer. The company also has an extensive patent portfolio covering its investigational drug as well as other therapeutic and diagnostic indications. It also has U.S. and patent rights for the use of statin drugs for the treatment and prevention of Alzheimer's disease. The company operates in one reportable segment, focused on researching and developing products for the aging population.
Quote snapshot
$0.0351
Daily change: —
ExchangeOTCPK
Updated2026-05-09T03:33:43.442983Z
Price chart
Price history
| Name |
|---|
| Revenue |
| Cost Of Goods Sold |
| Gross Profit |
| Gross Margin % |
| Research Development |
| Selling General Admin Expense |
| Depreciation Depletion Amortization |
| Other Operating Expense |
| Total Operating Expense |
| Operating Income |
| Operating Margin |
| Interest Income |
| Interest Expense |
| Other Income Expense |
| Other Income Minority Interest |
| Other Net Income Loss |
| Ebit |
| Ebitda |
| Ebitda Margin |
| Pretax Income |
| Tax Provision |
| Tax Rate |
| Net Income Continuing Operations |
| Net Income Discontinued Operations |
| Net Income |
| Net Income Including Noncontrolling Interests |
| Is Preferred Dividends |
| Shares Outstanding |
| Eps Basic |
| Eps Diluted |
| Net Margin |
SEC filings
Latest 10-K filing table
| Date | Form | Accession | Link |
|---|